Medpace (NASDAQ:MEDP) Downgraded by Zacks Research to Hold

Zacks Research downgraded shares of Medpace (NASDAQ:MEDP) from a strong-buy rating to a hold rating in a research report released on Monday morning,Zacks.com reports.

Other equities research analysts have also issued research reports about the stock. Weiss Ratings reaffirmed a “buy (b)” rating on shares of Medpace in a research note on Friday, October 31st. TD Cowen lifted their price objective on Medpace from $356.00 to $462.00 and gave the company a “sell” rating in a research report on Friday, October 24th. BMO Capital Markets assumed coverage on Medpace in a report on Thursday, November 13th. They set a “market perform” rating and a $600.00 target price on the stock. Cowen reissued a “sell” rating on shares of Medpace in a research report on Friday, October 24th. Finally, Truist Financial set a $555.00 price target on Medpace in a research note on Monday, October 27th. Two analysts have rated the stock with a Buy rating, eleven have given a Hold rating and four have given a Sell rating to the company. According to data from MarketBeat, the company presently has a consensus rating of “Reduce” and an average target price of $491.27.

Medpace Trading Down 0.2%

Shares of MEDP traded down $1.19 during mid-day trading on Monday, reaching $607.24. The company’s stock had a trading volume of 39,406 shares, compared to its average volume of 194,912. Medpace has a 52 week low of $250.05 and a 52 week high of $626.26. The stock has a market cap of $17.11 billion, a PE ratio of 42.54, a P/E/G ratio of 2.01 and a beta of 1.43. The company’s fifty day moving average price is $581.43 and its two-hundred day moving average price is $506.43.

Medpace (NASDAQ:MEDP) last released its earnings results on Wednesday, October 22nd. The company reported $3.86 earnings per share for the quarter, beating analysts’ consensus estimates of $3.50 by $0.36. Medpace had a return on equity of 91.88% and a net margin of 18.36%.The company had revenue of $659.90 million during the quarter, compared to analyst estimates of $640.49 million. During the same quarter in the previous year, the company posted $3.01 EPS. Medpace’s revenue for the quarter was up 23.7% on a year-over-year basis. Medpace has set its FY 2025 guidance at 14.600-14.860 EPS. Research analysts anticipate that Medpace will post 12.29 EPS for the current year.

Insider Activity

In related news, CFO Kevin M. Brady sold 3,000 shares of the firm’s stock in a transaction that occurred on Friday, November 21st. The shares were sold at an average price of $590.35, for a total value of $1,771,050.00. Following the sale, the chief financial officer owned 6,000 shares in the company, valued at approximately $3,542,100. This trade represents a 33.33% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, VP Susan E. Burwig sold 20,000 shares of Medpace stock in a transaction that occurred on Monday, November 24th. The stock was sold at an average price of $609.15, for a total transaction of $12,183,000.00. Following the completion of the sale, the vice president directly owned 27,500 shares of the company’s stock, valued at approximately $16,751,625. This trade represents a 42.11% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold a total of 387,925 shares of company stock valued at $233,386,647 in the last 90 days. 20.30% of the stock is currently owned by insiders.

Institutional Investors Weigh In On Medpace

A number of large investors have recently made changes to their positions in MEDP. AQR Capital Management LLC boosted its holdings in shares of Medpace by 65.1% in the third quarter. AQR Capital Management LLC now owns 1,025,410 shares of the company’s stock worth $518,170,000 after buying an additional 404,226 shares during the last quarter. Wasatch Advisors LP increased its stake in shares of Medpace by 14.0% in the 2nd quarter. Wasatch Advisors LP now owns 945,814 shares of the company’s stock worth $296,853,000 after purchasing an additional 116,354 shares in the last quarter. Mawer Investment Management Ltd. increased its stake in shares of Medpace by 17.4% in the 2nd quarter. Mawer Investment Management Ltd. now owns 817,432 shares of the company’s stock worth $256,559,000 after purchasing an additional 121,213 shares in the last quarter. Baillie Gifford & Co. raised its holdings in Medpace by 12.0% in the 3rd quarter. Baillie Gifford & Co. now owns 584,796 shares of the company’s stock worth $300,679,000 after purchasing an additional 62,503 shares during the period. Finally, Invesco Ltd. lifted its position in Medpace by 18.9% during the third quarter. Invesco Ltd. now owns 537,407 shares of the company’s stock valued at $276,313,000 after purchasing an additional 85,517 shares in the last quarter. 77.98% of the stock is currently owned by institutional investors.

About Medpace

Medpace Holdings, Inc (NASDAQ: MEDP) is a global contract research organization (CRO) that provides comprehensive clinical development services to biotechnology, pharmaceutical and medical device companies. The company supports clinical trials across all phases (I–IV), offering end-to-end solutions designed to streamline the development process and accelerate the delivery of new therapies to market.

Medpace’s core service offerings include clinical pharmacology, regulatory affairs consulting, project management, central laboratory services, imaging, data management and biostatistics, pharmacovigilance and medical writing.